|3.||Hepatocellular Carcinoma (Hepatoma)
|5.||Liver Cirrhosis (Hepatic Cirrhosis)
|1.||Poynard, Thierry: 77 articles (05/2015 - 02/2002)|
|2.||Nobili, Valerio: 69 articles (02/2016 - 01/2004)|
|3.||Lin, Han-Chieh: 68 articles (11/2015 - 01/2002)|
|4.||Zhang, Wei: 63 articles (01/2016 - 04/2002)|
|5.||Distler, Oliver: 62 articles (01/2016 - 10/2005)|
|6.||Li, Jun: 60 articles (01/2016 - 07/2004)|
|7.||Arroyo, Vicente: 59 articles (09/2015 - 01/2002)|
|8.||Distler, Jörg H W: 58 articles (01/2016 - 01/2007)|
|9.||Leask, Andrew: 57 articles (11/2015 - 04/2002)|
|10.||Sanyal, Arun J: 56 articles (11/2015 - 01/2003)|
12/01/2014 - "A significant decrease in collagen deposition and reduced expression of alpha-smooth muscle actin (α-SMA) protein indicated that IL-30-based gene therapy dramatically reduced bridging fibrosis that was induced by CCl4 or DDC. "
12/01/2013 - "Furthermore, DOW-AC also had more potent effect on protection against TAA-induced liver damage and fibrosis according to the results of H&E stain and collagen stain. "
04/03/2012 - "Compared with the group B, the pathological stages of hepatic fibrosis in group D and E were significantly reduced (P < 0.05), the expression of collagen were decreased, ultrastructural alterations were markedly improved. "
04/01/2009 - "More importantly, these changes in gene expression were associated with marked attenuation of lung fibrosis, including decreased collagen deposition and improved lung function and survival. "
01/01/1999 - "Finally, the observation that culture of RPT cells on a reconstituted basement membrane preparation results in a significant reduction in total collagen production and alterations in the molecular forms of type IV and type I molecules synthesized indicates that integrity of the tubular basement membrane may represent an important component in preventing the development of tubulointerstitial fibrosis."
|2.||Bleomycin (Blenoxane)FDA LinkGeneric
10/01/2015 - "In vivo FIZZ1 expression was significantly elevated in the murine bleomycin-induced dermal fibrosis model, which was associated with significant reduction in adipocyte marker gene expression and subcutaneous lipoatrophy. "
07/01/2014 - "Collectively, our findings strongly suggest that significant reduction of MC numbers does not affect skin wound healing and bleomycin-induced fibrosis in mice, and provide to our knowledge previously unreported insight in the long-debated contribution of MCs in skin regenerative processes. "
01/01/2009 - "Concomitantly, we observed a clear decrease in neutrophil infiltration and a significant reduction in the severity of bleomycin-induced lung fibrosis in mice treated with placenta-derived cells, irrespective of the source (allogeneic or xenogeneic) or delivery route. "
02/01/2005 - "The therapeutic efficacy of the bleomycins is limited by development of lung fibrosis. "
08/15/1989 - "Bleomycin (BLEO), an antitumor antibiotic effective against a variety of malignancies, has been associated classically with a pulmonary toxic reaction producing diffuse interstitial fibrosis. "
02/01/2012 - "Paired liver biopsies and blood tests were available for 101 patients, and there was a significant improvement in Metavir activity and a significant increase in blood tests reflecting fibrosis quantity in patients treated with interferon when compared with controls - all per cent changes in histological fibrosis measures were significantly increased in F1 vs F2-4 stages only in the interferon group. "
01/01/2011 - "Among patients treated with Interferon-based therapy, those with sustained viral response showed a significant reduction of progression to cirrhosis and development of HCC. "
01/01/1999 - "This overview provides evidence that interferon in patients who have not cleared hepatitis C virus (HCV) significantly reduces viral load, serum ALT activity, improves histological activity and blocks progression of fibrosis compared to the natural history of the disease. "
05/01/2012 - "In a pilot study, we have investigated the efficacy of an escalating dose of pegylated interferon α-2a (PEG-IFN2a) as compared with standard clinical care in patients with more advanced HCV Child's A or B cirrhosis without a lead-in phase. "
10/01/2004 - "In contrast, protection against hepatic fibrosis is dependent on interferon (IFN)-gamma and is controlled by a major genetic locus that is located on 6q23, near the gene encoding the IFN-gamma receptor beta chain. "
|4.||Non-alcoholic Fatty Liver DiseaseIBA
07/21/2014 - "Notably, GLP-1-based therapies are reported to be effective in improving hepatic endpoints in patients with NAFLD, such as reducing hepatic fat content, hepatic steatosis and plasma transaminase levels, and preventing fibrosis. "
10/01/2013 - "However, the efficacy of peripherally-restricted CB1 antagonists with limited brain penetrance has now been validated in preclinical models of NAFLD, and beneficial effects on fibrosis and its complications are anticipated. "
06/01/2013 - "Besides, NAFLD fibrosis score underlined a significant reduction (p < 0.04) in the ALAUDCA group, while AST/ALT ratio presented a moderate decline (p > 0.05). "
03/01/2011 - "These modalities and algorithms have improved significantly in their diagnosis and staging of fibrosis and NASH in patients with NAFLD, and will likely impact on the number of patients undergoing liver biopsy. "
10/01/2015 - "Our preliminary findings indicate that FibroMeter VCTE is superior to both NFSA and TE for the diagnosis of severe fibrosis in patients with NAFLD."
|5.||Ribavirin (Virazole)FDA LinkGeneric
12/01/2006 - "Thus, (1) patients with genotypes 2 and 3 and severe fibrosis can be treated with low dose of Peg-IFN and ribavirin, (2) this study suggests that patients with genotypes 1, 4 and 5 and high viraemia could receive a standard dose of Peg-IFN associated with ribavirin for 48 weeks, (3) side effects limit the efficacy of the treatment with standard dose of Peg-IFN in patients with genotypes 1, 4 and 5 and low viraemia, (4) more studies are needed for patients with genotype 2 or 3 to define the optimal duration (24 or 48 weeks) in patients with severe fibrosis."
04/24/2010 - "Relapse risk increased in patients with cirrhosis, in those with ribavirin dose reductions and in late responders: more than 65% of patients who cleared the virus between weeks 12 and 24 relapsed following 48 weeks of treatment compared with 10% of those attaining a complete EVR (<15 IU/ml) at treatment week 12 (risk ratio 6.4, 95% confidence interval 2.9-14.4). "
01/01/2008 - "Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis."
08/01/2015 - "Ribavirin is required only for some treatment regimens and may be particularly beneficial in patients with cirrhosis. "
04/01/2000 - "Although current evidence suggests that the combination of ribavirin and IFN-alpha might be more efficacious than IFN alone in increasing the response rate in patients in the advanced fibrotic stage, the efficacy of this regimen for patients with well-compensated HCV-related cirrhosis is still unknown and prospective well-designed studies are urgently needed. "
|6.||Transforming Growth Factor beta (TGF-beta)IBA
12/01/1993 - "The density of the antimacrophage (M phi) antibody positive cells in the muscular layers was apparently greater in the remarkable fibrosis group than in the unremarkable fibrosis group, and the density of the anti-TGF-beta antibody positive cells in the remarkable fibrosis group was significantly greater than in the unremarkable fibrosis group. "
02/01/2006 - "While high levels of TGF-beta appeared to be associated with protection against fibrosis, the strength of the association was low."
05/01/1988 - "These findings suggest that TGF-beta secreted in an inflammatory site may be beneficial in diminishing lymphocyte function while promoting fibrosis and tissue repair. "
01/01/2013 - "These results demonstrate that class I HDACs are critically involved in renal fibrogenesis and renal fibroblast activation through modulating TGF-beta and EGFR signaling and suggest that blockade of class I HDAC may be a useful treatment for renal fibrosis."
06/01/2009 - "EMT antagonists, TGF-beta signal modulator, and HIF-1alpha inhibitor could be useful for the treatment of fibrosis."
|7.||Lamivudine (3TC)FDA Link
12/01/2002 - "Although several clinical trials have suggested that lamivudine treatment can be very effective in patients with decompensated HBV-associated cirrhosis, its role and clinical efficacy are still uncertain because of the study designs. "
04/01/2007 - "It has been statistically proven that the efficacy of lamivudine therapy correlates with degree of fibrosis and higher histological activity index values. "
09/01/2003 - "Significant improvement in liver histology, both necroinflammation and fibrosis, can be obtained in the majority of patients treated with lamivudine for one year."
01/01/2003 - "One-year of Lamivudine treatment significantly improved necroinflammation and reduced the progression of fibrosis and the histologic activity index. "
07/01/2000 - "One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. "
|8.||Biological Markers (Surrogate Marker)IBA
09/01/2011 - "ABMi for patients with ALC helps improve liver function parameters in comparison with observation during abstinence and ameliorates the degree of fibrosis in terms of serum markers and bone marrow activation in most cases."
08/01/2012 - "Our study suggests that serum biomarkers may help to diagnose significant fibrosis but inadequate to detect fibrosis in early stages. "
10/01/2011 - "Despite the rapid progress in recent years, there remain questions about how diagnostic studies are designed, statistical methods to account for spectrum bias, clinically relevant thresholds of fibrosis that should be delineated, how diagnostics can be improved, and strengthening the reference test to judge emerging biomarkers. "
04/01/2011 - "The Clinical Score (CS) model using only routine clinical data and the Biomarker Score (BS) model using 7 putative biomarkers were derived from the derivation set (n=105), and these models were applied to a separate patients group (n=104) to investigate whether the addition of BS improved the diagnostic accuracy in predicting significant fibrosis beyond an assessment based solely on CS. "
12/01/2007 - "However, the efficacy of using direct and indirect serum markers to predict significant fibrosis in clinical practice is inconclusive. "
|9.||Messenger RNA (mRNA)IBA
10/01/2008 - "Moreover, it dramatically reduced hepatic inflammatory changes and fibrosis concomitantly with marked reductions in the mRNA levels for inflammatory cytokine, chemokine, and profibrogenic genes. "
01/01/2016 - "In this study, we found that mRNA and protein levels of HDAC6 were upregulated in cardiac fibrosis tissues and activated cardiac fibroblast cells. "
01/01/2014 - "Results of this study demonstrated that ARB administration significantly decreased arteriolopathy and that in comparison with monotherapy, concomitant administration of MZR and ARB further decreased arteriolopathy, fibrosis, macrophage infiltration, and TGF-β1 mRNA expression associated with CsA nephrotoxicity. "
08/01/2008 - "In acute study using a single drug injection, we observed a rapid transient increase of ALT and mRNA levels of KLF5 followed by increases in fibrosis-related genes. "
12/01/2005 - "We used real-time quantitative RT PCR to study the messenger RNA expression of 240 selected genes in 2 pools of liver specimens according to the stages of fibrosis (Metavir score; mild fibrosis = F1 and septal fibrosis = F2). "
|10.||Transforming Growth Factor beta1 (TGF beta 1)IBA
09/01/2010 - "Short-term blockade of TGF-beta1 function after radiation markedly decreased tissue fibrosis and significantly improved lymphatic function but did not alter LEC apoptosis. "
10/01/2007 - "Significant reduction of fibrosis and TGF-beta1 expression was found in the muscles of the scid/mdx mice. "
06/01/2006 - "Significantly greater fibrosis and TGF-beta1 expression were found in mdx from the 6th week. "
08/01/2002 - "It also improved significantly histological changes of fibrosis and decreased the expression of alpha-SMA and TGF-beta1 in liver of these rats (P<0.05 or P<0.01). "
04/01/1999 - "The neutralization of TGF-beta1 has been beneficial in the reduction of fibrosis. "
01/01/2010 - "Liver transplantation is the best treatment for HCC; it improves survival, cures cirrhosis, and abolishes local recurrence. "
01/01/2007 - "Liver transplantation provides the best cure for both the HCC and the underlying cirrhosis. "
07/01/2005 - "Percutaneous ablation is considered the best treatment option for patients with Child-Pugh class A or B cirrhosis and a single, nodular-type HCC smaller than 5 cm or as many as three HCC lesions, each smaller than 3 cm, when surgical resection or liver transplantation is not suitable. "
11/01/2004 - "For Child class B and C patients with a small HCC, liver transplantation offers the best results, whereas partial liver resection is indicated in patients with well-compensated cirrhosis. "
09/01/2003 - "The best results of liver transplantation were achieved in patients transplanted on a routine basis with a diagnosis of PBC (91.4%), autoimmunologic cirrhosis (81.1%), postalcoholic cirrhosis (80%), or hemochoromatosis (100%). "
|2.||Transplantation (Transplant Recipients)
06/01/2009 - "Early free functional muscle transplantation shows best results in patients with direct muscle defect, because all vascular and neuronal structures are still available, and no secondary changes such as fibrosis or joint stiffness are present yet. "
04/01/2003 - "Amniotic membrane combined with limbal autograft is more effective in the treatment of recurrence or pseudopterygium than amniotic membrane transplantation, and is able to inhibit fibrosis, reconstruct the ocular surface and promote the epithelial recovery, so as to improve the curative effect and decrease the recurrence."
01/01/2014 - "The interstitial fibrosis ("ci") score, according to the Banff classification, was significantly greater in the NTx group (0.89) than in the Tx group (0.50) at 1 year after transplantation. "
10/27/2013 - "Four weeks after transplantation, both allogeneic FM-MSC and autologous BM-MSC sheets had significantly improved cardiac function and reduced myocardial fibrosis compared with the untreated MI group. "
10/01/2012 - "This was associated with significantly improved cardiac performance as measured by dp/dt(max), dp/dt(min), LVEDP and LVDP, declined left ventricle (LV) fibrosis and apoptosis as measured by Masson's Trichrome and TUNEL assays, respectively, after 30 days of transplantation. "
12/01/2002 - "In one patient the fibrosis resolved completely 180 d post transplant. "
12/01/2013 - "After engraftment in the Lewis rat recipient, renal function was significantly improved in the Xe-treated grafts, and macrophage infiltration and fibrosis were reduced. "
05/01/2000 - "The rate of global obsolescence, and the degree of interstitial fibrosis in post-transplant IgAN were significantly greater than in primary IgAN (P<0.05). "
03/15/1992 - "Wall thickness was significantly greater in the vein grafts after long-term implantation than in the freshly harvested veins (average thickness 1.4 +/- 0.5 vs. 0.7 +/- 0.2 mm, p less than 0.007); this finding correlated histologically with vein wall fibrosis. "
08/01/1990 - "Grafts and donor sites treated with direct current showed more rapid reepithelialization, decreased contraction, improved hair survival, and decreased dermal fibrosis when compared to controls not treated with direct current. "
08/01/2011 - "Further, the protective effects of UA on progression of hepatic fibrosis caused by TAA and bile duct ligation (BDL) were evaluated. "
01/01/2015 - "To investigate the efficacy of diffusion-weighted magnetic resonance imaging (DWI) in the diagnosis and staging of fibrosis induced by experimental bile duct ligation (BDL). "
12/01/2014 - "When MMI-0100 peptide was given 30 min after permanent LAD coronary artery ligation, the resulting fibrosis was reduced/prevented ~50% at a 2 week time point, with a corresponding improvement in cardiac function and decrease in left ventricular dilation. "
07/01/2009 - "c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice."
09/01/2015 - "To study this thesis, we studied two murine models of fibrosis, first, common bile duct ligation (CBDL) and second, feeding of 3, 5-diethoxy-carbonyl-1, 4-dihydrocollidine (DDC). "
07/01/1991 - "Sclerotherapy was most effective in patients of (EHO), than (NCPF) followed by cirrhosis of the liver."
11/01/1994 - "Sclerotherapy was not found to improve survival in patients, irrespective of the etiology of cirrhosis (alcoholic or nonalcoholic) or variceal size (low-grade or high-grade). "
01/01/1998 - "The purpose of this multicenter, randomized controlled trial is to compare the efficacy of TIPS with that of endoscopic sclerotherapy in the prevention of variceal rebleeding in cirrhosis. "
12/30/1996 - "The methodology is illustrated using data from 26 clinical trials which investigate the prevention of cirrhosis using beta-blockers and sclerotherapy. "
01/01/1988 - "In our study, we examined the effects of prophylactic sclerotherapy on esophageal motility in 15 patients with Child's A cirrhosis of the liver. "